We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Point of Care Testing Market Driven by New Molecular Diagnostic Technologies

By LabMedica International staff writers
Posted on 14 Jul 2022
Print article
Image: The global POC testing market is expected to surpass USD 70 billion by 2030 (Photo courtesy of Global Market Insights)
Image: The global POC testing market is expected to surpass USD 70 billion by 2030 (Photo courtesy of Global Market Insights)

The global point of care (POC) testing market is projected to reach USD 70.8 billion by 2030, driven by an increasing number of pathology labs and services equipped with advanced diagnostic equipment. Molecular testing technology allows nucleic acid detection directly through amplification and screening of sample. As a result, industry players have been focusing their efforts on developing new POC molecular diagnostic technologies to deliver faster results with high accuracy and specificity. Thus, the introduction of new POC molecular diagnostic technologies that deliver faster results with high accuracy and specificity will positively impact the market growth.

These are the latest findings of Global Market Insights Inc. (Selbyville, DE, USA), a market research and strategy consulting firm.

Based on product, the cardiometabolic testing products segment dominated the global POC testing market with revenue of more than USD 3.6 billion in 2021. Greater affordability and convenience over conventional testing along with the availability of several cardiometabolic testing products is expected to continue driving the segment’s growth. Based on technology, the immunoassay segment accounted for the highest revenue share of 17.7% of the global POC testing market in 2021 and is expected to register a significant CAGR through 2030. Immunoassay is a highly selective bioanalytical technique used to determine the presence or quantity of analytes ranging from micro molecules to macro molecules in a solution. This technique provides quick, cost effective and simple methods for detection with high sensitivity and precise results.

Based on prescription, the home-care settings segment is set to dominate the global POC testing market with revenues surpassing USD 18.2 billion by 2030. This can be attributed to the introduction of several monitoring device and other devices that do not require training for operating. Such devices reduce dependency on professionals and offer owners the liberty to monitor, keep a track of glucose levels and manage diabetes efficiently in their home-care setting. Geographically, the POC testing market in Asia Pacific is projected to register a CAGR of 9.5% over the forecast period, driven by the increasing prevalence of infectious diseases, novel product launches and rising government healthcare expenditure. The European POC testing market is expected to be driven by favorable government initiatives and programs, rapidly evolving POCT techniques for diagnosing infectious diseases, and technological improvements & innovations for more appropriate and rapid testing products in the region.

Related Links:
Global Market Insights Inc. 

Gold Supplier
ESR Analyzer
miniiSED™
New
Gold Supplier
Automated Nucleic Acid Extraction Workstation
SAW-96
New
Lactose Intolerance Test
Lactose Intolerance LCT Kit
New
COL-R Assay
CHROMagar COL-APSE

Print article

Channels

Molecular Diagnostics

view channel
Image: The new multiplex QIAstat-Dx Viral Vesicular Panel is designed to support research and surveillance efforts (Photo courtesy of QIAGEN)

First Syndromic Test Differentiates Between Monkeypox and Five Pathogens with Similar Symptoms

A new syndromic test differentiates between monkeypox and five other pathogens which cause similar symptoms. This first-ever test detects the two known forms of monkeypox virus (the so-called West African... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.